AIA Group Ltd Has $23.40 Million Stake in Pfizer Inc. $PFE

AIA Group Ltd raised its holdings in Pfizer Inc. (NYSE:PFE) by 14.7% in the 1st quarter, HoldingsChannel reports. The firm owned 833,363 shares of the biopharmaceutical company’s stock after purchasing an additional 106,683 shares during the quarter. AIA Group Ltd’s holdings in Pfizer were worth $23,401,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. lifted its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares in the last quarter. Horizon Financial Services LLC increased its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. YANKCOM Partnership bought a new position in shares of Pfizer in the fourth quarter worth about $28,000. Finally, HFM Investment Advisors LLC raised its stake in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PFE. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Guggenheim dropped their price objective on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. UBS Group reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech…

Pfizer Price Performance

Shares of PFE stock opened at $25.08 on Friday. The firm’s 50 day moving average price is $25.21 and its two-hundred day moving average price is $26.17. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The stock has a market cap of $142.94 billion, a PE ratio of 19.15 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.